Tuesday, August 30, 2022

For Common Form of Bladder Cancer, Chemo Combo Effective Alternative to BCG - Cancer Currents Blog

National Cancer Institute

Having trouble viewing this email? View it as a Web page.

Bookmark and Share

You are subscribed to Cancer Currents: An NCI Cancer Research Blog from the National Cancer Institute. Recent posts are listed below.

 

 

08/29/2022
The standard treatment for high-risk non-muscle-invasive bladder cancer (NMIBC), a drug called BCG, has been in shortage for a decade. Bladder cancer experts agree that gemcitabine and docetaxel offers an effective alternative to BCG, after a study showed that 82% of patients with high-risk NMIBC treated with the combination were alive 2 years later without their cancer returning.
This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Cancer Institute · BG 9609 MSC 9760 · 9609 Medical Center Drive · Bethesda, MD 20892 GovDelivery logo

No comments:

Post a Comment